This story is just the latest example in the ongoing issues GLP-1s face when it comes to coverage. As a result, coverage providers have struggled to include the medications, especially considering the wide swath of indications they can be prescribed for. Pharmaceutical Executive spoke with Susan Thomas, chief commercial officer at LucyRx, about the company’s efforts to provide coverage models for GLP-1s and why its so important to provide these medications for general health purposes. Pharmaceutical Executive: What is the business case for employer-based GLP-1 coverage? That's the population that often loses coverage when plan sponsors decide to exclude obesity as an indication.